Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Nauseef, Jones T.
Thomas, Charlene
Ho, Benedict
Zuloaga, Juana Martinez
Gonzalez, Brian D.
Sun, Michael
Sartor, A. Oliver
Singh, Sharon
Bissassar, Mahelia
Fernandez, Escarleth
Tan, Angela
Patel, Amie
Naiz, Muhammad Obaid
Vallabhajosula, Shankar
Molina, Ana M.
Sternberg, Cora N.
Nanus, David M.
Osborne, Joseph
Bander, Neil Harrison
Tagawa, Scott T.
机构：
[1] New York Presbyterian Hosp, Weill Cornell Med Ctr, New York, NY USA
[2] Weill Cornell Med, New York, NY USA
[3] Cornell Univ, Ithaca, NY USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] Tulane Med Sch, Sch Med, New Orleans, LA USA
[6] Weill Cornell Med Ctr, New York, NY USA
[7] Weill Cornell Med, Englander Inst Precis Med, Hematol Oncol, New York, NY USA
[8] Sandra & Edward Meyer Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.077
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
77
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase I/II dose-escalation trial of fractionated dose 177Lu-J591 plus 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Niaz, Muhammad Junaid
    Osborne, Joseph
    Vallabhajosula, Shankar
    Beltran, Himisha
    Harshman, Lauren Christine
    Nanus, David M.
    Molina, Ana M.
    Faltas, Bishoy Morris
    Hackett, Amy
    Gracey, Lauren
    Sreekumar, Jyothi
    Babich, John
    Ballman, Karla V.
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [22] Analysis of the temporal relationship between patient-reported outcomes (PROs) and overall survival (OS) and radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
    Traina, Shana
    Li, Tracy
    Johnson, Kristen
    Ho, Kai Fai
    Molina, Arturo
    Cella, David
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [23] Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT).
    Sun, Michael
    Thomas, Charlene
    Ho, Benedict
    Niaz, Muhammad Junaid
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody 177lu-J591 in patients with metastatic, castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Whang, Young E.
    Kaur, Gurveen
    Vallabhajosula, Shankar
    Christos, Paul J.
    Nikolopoulou, Anastasia
    Jhanwar, Yuliya
    Sheikh, Arif
    Ireland, Adam
    Garcias-Espana, Carmen
    Goldsmith, Stanley J.
    Beltran, Himisha
    Bander, Neil Harrison
    Nanus, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.
    Lebenthal, Justin M.
    Sun, Michael
    Nauseef, Jones T.
    Niaz, Muhammad Junaid
    Imad, Dunya
    Christos, Paul J.
    Fernandez, Escarleth
    Singh, Sharon
    Chamberlain, Tessa A.
    Osborne, Joseph
    Babich, John
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [26] 225Actinium and combined 225Actinium/177Lutetiumlabelled (TANDEM) PSMA radioligand therapy (PRLT) in patients with metastatic castration resistant prostate cancer (mCRPC): A retrospective study on long-term adverse events and survival
    Perrone, E.
    Mishra, A.
    Eismant, A.
    Ghai, K.
    Greifenstein, L.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S360 - S360
  • [27] 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603).
    Hofman, Michael S.
    Emmett, Louise
    Sandhu, Shahneen Kaur
    Iravani, Amir
    Joshua, Anthony M.
    Goh, Jeffrey C.
    Pattison, David A.
    Tan, Thean Hsiang
    Kirkwood, Ian D.
    Ng, Siobhan
    Francis, Roslyn J.
    Gedye, Craig
    Rutherford, Natalie K.
    Zhang, Alison Yan
    McJannett, Margaret Mary
    Stockler, Martin R.
    Violet, John A.
    Williams, Scott
    Martin, Andrew James
    Davis, Ian D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [28] Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer
    Perrone, Elisabetta
    Giordano, Alessandro
    Calcagni, Maria Lucia
    Leccisotti, Lucia
    Moretti, Roberto
    Eismant, Aleksandr
    Ghai, Kriti
    Parkar, Tanay
    Mishra, Aditi
    Heidenreich, Axel
    Wirtz, Ralph M.
    Mueller, Joerg
    Greifenstein, Lukas
    Baum, Richard P.
    CANCERS, 2025, 17 (03)
  • [29] Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
    Delpassand, Ebrahim S.
    Hashmi, Mohammad Jawed
    Kazakin, Julia
    Nawaz, Omer
    Garufi, Gabriella
    Schindler, Joanne
    Nordquist, Luke
    CANCER RESEARCH, 2024, 84 (07)
  • [30] Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).
    Mehra, Niven
    Antonarakis, Emmanuel S.
    Park, Se Hoon
    Goh, Jeffrey C.
    McDermott, Raymond S.
    Gonzalez, Nuria Sala
    Fong, Peter C. C.
    Greil, Richard
    De Santis, Maria
    Yanez, Patricio Eduardo
    Huang, Yi-Hsiu
    Begbie, Stephen
    Rey, Felipe
    Kramer, Gero
    Suzuki, Hiroyoshi
    Saretsky, Todd L.
    Ghate, Sameer R.
    Cui, Yi
    Kim, Jeri
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345